These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9192773)

  • 1. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40.
    Francisco JA; Schreiber GJ; Comereski CR; Mezza LE; Warner GL; Davidson TJ; Ledbetter JA; Siegall CB
    Blood; 1997 Jun; 89(12):4493-500. PubMed ID: 9192773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies.
    Francisco JA; Siegall CB
    Leuk Lymphoma; 1998 Jul; 30(3-4):237-45. PubMed ID: 9713956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
    Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
    Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
    Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
    J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
    Friedman PN; Chace DF; Trail PA; Siegall CB
    J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1.
    Francisco JA; Gawlak SL; Siegall CB
    J Biol Chem; 1997 Sep; 272(39):24165-9. PubMed ID: 9305866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin.
    Francisco JA; Kiener PA; Moran-Davis P; Ledbetter JA; Siegall CB
    J Immunol; 1996 Aug; 157(4):1652-8. PubMed ID: 8759752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
    Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
    Siegall CB
    Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells.
    Uckun FM; Gajl-Peczalska K; Myers DE; Jaszcz W; Haissig S; Ledbetter JA
    Blood; 1990 Dec; 76(12):2449-56. PubMed ID: 1702326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
    Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
    Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
    Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
    J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
    Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
    Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
    Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
    Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
    J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
    Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.